ABVC BioPharma, Inc. is asking stockholders to authorize up to 1,600,653 common shares at no less than $1.00 per share as potential consideration for proposed acquisitions of land in Taoyuan and real property in Hualien, Taiwan. The proposed seller is director Shuling Jiang. Consideration would consist solely of shares, with no cash; the final purchase price and share count remain under negotiation, and no definitive purchase agreement has been executed. The properties’ aggregate appraised value is approximately US$622,291, not a finalized purchase price.
Stockholders will also consider the 2026 Equity Incentive Plan and ratification of 600,000 shares awarded to two advisors between February 16 and September 11, 2026. If approved, the plan’s share pool would start with 1,169,201 shares plus 15% of common shares outstanding on the meeting date; annual additions equal to 5% of shares outstanding on the prior December 31 would begin January 1, 2027, through the plan’s last effective year. The virtual meeting is October 28, 2026; 26,694,476 common shares were outstanding on September 14, 2026, the record date.
ABVC BIOPHARMA, INC. (symbol: ABVC) is the issuer of record for a Form 8-K filing submitted to the SEC.